BioTelemetry Inc (NASDAQ:BEAT) – Research analysts at Dougherty & Co issued their Q4 2018 earnings per share estimates for shares of BioTelemetry in a report issued on Wednesday, October 31st. Dougherty & Co analyst G. Mannheimer forecasts that the medical research company will earn $0.41 per share for the quarter. Dougherty & Co also issued estimates for BioTelemetry’s FY2019 earnings at $1.59 EPS.
Other equities research analysts also recently issued reports about the company. SunTrust Banks increased their price target on BioTelemetry to $67.00 and gave the stock a “buy” rating in a research report on Friday, August 31st. Lake Street Capital raised their target price on BioTelemetry from $50.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, July 26th. BidaskClub cut BioTelemetry from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 4th. Finally, Raymond James dropped their target price on BioTelemetry from $66.00 to $64.00 and set an “outperform” rating on the stock in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $61.17.
BEAT traded up $3.32 during midday trading on Friday, hitting $64.95. 11,883 shares of the company were exchanged, compared to its average volume of 446,053. The company has a market capitalization of $1.67 billion, a P/E ratio of 67.01, a P/E/G ratio of 3.37 and a beta of 1.41. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.12 and a current ratio of 2.29. BioTelemetry has a 1-year low of $23.30 and a 1-year high of $66.02.
BioTelemetry (NASDAQ:BEAT) last announced its quarterly earnings results on Tuesday, October 30th. The medical research company reported $0.53 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.21. The company had revenue of $100.00 million for the quarter, compared to the consensus estimate of $97.89 million. BioTelemetry had a return on equity of 23.33% and a net margin of 4.34%. The firm’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same period last year, the firm earned $0.16 EPS.
In other news, Director Kirk E. Gorman sold 625 shares of the firm’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $65.07, for a total transaction of $40,668.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Fred Broadway sold 90,113 shares of the firm’s stock in a transaction dated Friday, September 28th. The shares were sold at an average price of $65.00, for a total value of $5,857,345.00. The disclosure for this sale can be found here. Insiders have sold a total of 122,363 shares of company stock worth $7,810,901 over the last 90 days. Insiders own 9.60% of the company’s stock.
Large investors have recently bought and sold shares of the company. BlackRock Inc. lifted its stake in BioTelemetry by 8.0% in the 2nd quarter. BlackRock Inc. now owns 4,597,288 shares of the medical research company’s stock valued at $206,877,000 after buying an additional 339,306 shares in the last quarter. Castleark Management LLC purchased a new position in BioTelemetry in the 2nd quarter valued at about $13,712,000. Millennium Management LLC lifted its stake in BioTelemetry by 137.3% in the 2nd quarter. Millennium Management LLC now owns 185,208 shares of the medical research company’s stock valued at $8,334,000 after buying an additional 107,166 shares in the last quarter. EAM Investors LLC purchased a new position in BioTelemetry in the 2nd quarter valued at about $4,591,000. Finally, JPMorgan Chase & Co. lifted its stake in BioTelemetry by 230.8% in the 1st quarter. JPMorgan Chase & Co. now owns 96,032 shares of the medical research company’s stock valued at $2,982,000 after buying an additional 67,002 shares in the last quarter. Hedge funds and other institutional investors own 93.55% of the company’s stock.
BioTelemetry Company Profile
BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.
Recommended Story: Understanding Market Liquidity
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.